Antiviral compounds to inhibit the replicase of hepatitis C virus. Hepatitis C virus is a major public health problem. There are currently 200,000 infected individuals in Australia and 16,000 new infections every year. There is no specific treatment and current therapy treats a small percentage of patients only, which consists of interferon-alpha and ribavirin. This results in side effects and only a 50% cure rate. This study's outcomes are expected to lead to greater access to treatment and imp ....Antiviral compounds to inhibit the replicase of hepatitis C virus. Hepatitis C virus is a major public health problem. There are currently 200,000 infected individuals in Australia and 16,000 new infections every year. There is no specific treatment and current therapy treats a small percentage of patients only, which consists of interferon-alpha and ribavirin. This results in side effects and only a 50% cure rate. This study's outcomes are expected to lead to greater access to treatment and improved therapy resulting in higher cure rates and in a dramatic reduction in the cost of treating patients. A novel therapy will provide considerable benefits for the national biotechnology industry.Read moreRead less
Establishment Of A Bank Of Third Party T Cells To Treat Virus Infections (that Are Resistant Or Unsuitable For Other Forms Of Antibiotic Therapy) In Immunocompromised And Transplant Patients Across Australia
Funder
National Health and Medical Research Council
Funding Amount
$811,530.00
Summary
Bone marrow transplantation can cure cancers of the blood but patients are susceptible to viral infections due to ongoing immune deficiency. We have shown you can grow immune cells in the laboratory and transfer this immunity to transplant recipients. While effective, this has not been widely adopted due to the time, complexity and costs of the process. We aim to address these issues by providing a treatment option for patients with life threatening infections using immediately available “off th ....Bone marrow transplantation can cure cancers of the blood but patients are susceptible to viral infections due to ongoing immune deficiency. We have shown you can grow immune cells in the laboratory and transfer this immunity to transplant recipients. While effective, this has not been widely adopted due to the time, complexity and costs of the process. We aim to address these issues by providing a treatment option for patients with life threatening infections using immediately available “off the shelf” immune cells.Read moreRead less
Endothelial Dysfunction As A Therapeutic Target In Severe Malaria
Funder
National Health and Medical Research Council
Funding Amount
$842,329.00
Summary
Even with very best drugs to kill malaria parasites, over 15% of patients with severe malaria still die. Their blood vessels are clogged up by malaria parasites. We have shown that the cells lining their blood vessels can't make enough nitric oxide to keep them non-sticky and allow blood through. We want to test whether giving arginine can 1) increase nitric oxide, 2) open up the clogged blood vessels and 3) dampen down other processes that clog up blood vessels in severe malaria.